Last reviewed · How we verify
Sabin strain inactivated polio vaccine
At a glance
| Generic name | Sabin strain inactivated polio vaccine |
|---|---|
| Sponsor | Centers for Disease Control and Prevention, China |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine (PHASE4)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell) (PHASE3)
- A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine (PHASE3)
- Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028) (PHASE1)
- Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074) (PHASE3)
- Phase IV Study of Concomitant Administration of the sIPV and HepA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: